Why Elekta stock moves
Elekta fell slightly as the market fell clearly.
Written after the close on ·
Why today
15,876 news analyzed todayElekta fell slightly as the market fell clearly.
Elekta moved in line with OMX Stockholm 30 that day.
It was an ordinary day for Elekta, within its usual daily range.
No company news from the last session explains the move.
Over the last five trading days Elekta rose slightly while the market stayed roughly flat.
Today's move of −0.74% was 0.7 times a normal day's 1.1%. OMX Stockholm 30 moved −1.01% on the same day.
Elekta −0.74%OMX Stockholm 30 −1.01%In step with the market
What analysts expect, and how often they have been right
Analysts’ estimates for Elekta.
Elekta earned more than expected in 4 out of 8 reports.
For comparison, about 46% of reports from Nordic companies beat the estimate in the last three years.
The share moved in the same direction as the earnings surprise in 3 out of 6 reports with a measured move, against about 63% of reports from Nordic companies.
Ratings
Price targets
Latest price 60.75 SEK
Earnings against expectations, and the share’s reaction
Expected EPSAbove estimateBelow estimateAs expectedSEK
Next reported quarter: expected earnings per share of 0.75 SEK (November 25). For the current fiscal year, expected earnings per share changed from 3.90 SEK three months ago to 3.89 SEK now. 2027 estimate: 3.89 SEK. 2028 estimate: 4.23 SEK. People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor. September 24: Sell about 323 thousand SEK. September 17: Buy about 188 thousand SEK. September 11: Buy about 9.9 m SEK. July 6: Buy about 518 thousand SEK. June 26: Buy about 1.1 m SEK.
Has the share price followed the business?
Price and earnings moved in the same direction: 1 out of 3 years. Across Nordic companies, that happens in about 60% of years. In 2026, the price changed +9% and earnings per share went from 0.62 SEK to -1.36 SEK.
Revenue, profit and market cap
RevenueProfitMarket capHatched bars: analysts’ estimates.bn SEK
Assets, liabilities and market cap
AssetsLiabilitiesMarket capbn SEK
Price and earnings moved in the same direction: 1 out of 3 years.Market cap (Now): 23.2 bn SEKRevenue 2026: 16.7 bn SEK
What the key figures say about Elekta
The figures connect what Elekta earns with what investors pay.
The line shows the share price in the same year, on its own scale. Hatched bars: analysts’ estimates.
Profit divided by the number of shares. Each share represents this much of the earnings.
2023–2026: -1.36 SEK–3.41 SEK. Peers: GN Store Nord -1.15 DKK, Embla Medical 1.42 DKK, Ambu 2.42 DKK. 2027 estimate: 3.89 SEK (3.24 SEK–4.43 SEK). 2028 estimate: 4.23 SEK (3.27 SEK–4.95 SEK).
What the company sold during the year.
2023–2026: 16.7 bn SEK–18.1 bn SEK. Peers: GN Store Nord 14.8 bn DKK, Embla Medical $997M, Ambu 6.2 bn DKK. 2027 estimate: 17.3 bn SEK (16.5 bn SEK–17.6 bn SEK). 2028 estimate: 18.0 bn SEK (16.9 bn SEK–18.4 bn SEK).
The percentage of revenue left after the costs of running the business.
2023–2026: 0.6%–12.5%. Peers: GN Store Nord 3.6%, Embla Medical 13.6%.
Profit as a percentage of shareholders’ money in the company.
2023–2026: −7.3%–12.1%. Peers: GN Store Nord 2.6%, Embla Medical 10.4%, Ambu 8.4%.
What investors pay for each unit the company sells.
2023–2026: 1.04–1.95. Peers: GN Store Nord 1.22, Ambu 3.66. 2027 estimate: 1.34. 2028 estimate: 1.29.
Money paid to shareholders per share, summed by calendar year.
2017–2025: 0.75 SEK–2.40 SEK.
The ordinary yearly dividend as a percentage of the share price.
2023–2026: 2.8%–4.9%. Peers: GN Store Nord 0.0%, Embla Medical 0.0%, Ambu 0.5%.
Net debt divided by operating earnings before depreciation and amortisation.
2023–2026: 1.32–2.95. Peers: GN Store Nord 3.56, Embla Medical 2.62, Ambu -0.14.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2023–2026: 2.13–3.38. Peers: GN Store Nord 1.71, Ambu 3.76.
Market cap plus net debt, divided by operating earnings. This includes debt.
2023–2026: 17.1–150.4.
Cash left after investments, divided by the number of shares.
2023–2026: 1.05 SEK–3.64 SEK. Peers: GN Store Nord 0.92 DKK, Embla Medical $0.25.
The percentage of assets financed by shareholders’ equity.
2023–2026: 26.3%–34.3%.
The dividend explained
A dividend is money paid to shareholders. Elekta paid 2.40 SEK per share in the twelve months through November 6, 2026.
On the ex-dividend day, September 4, 2026, Elekta traded without the right to the 1.20 SEK dividend. The price went from 53.00 SEK to 52.30 SEK; including the dividend, the day's change was +0.9%. Entitlement passes from the company to shareholders on the ex-day; payment comes later.
2017: 0.75 SEK2018: 1.20 SEK2019: 1.60 SEK2020: 1.80 SEK2021: 2.00 SEK2022: 2.30 SEK2023: 2.40 SEK2024: 2.40 SEK2025: 2.40 SEK2026 so far: 2.40 SEK
What to watch next, and why
The earnings report shows how Elekta's revenue and profit have changed.
- Earnings report
The earnings report shows how Elekta's revenue and profit have changed.
Add to calendar - The dividend explained
From the ex-day, Elekta trades without entitlement to the next dividend.
More about Elekta
Insider trades
People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor.
- John Lapre, senior executiveSellabout 323 thousand SEK
- Klara Eiritz, CFOBuyabout 188 thousand SEK
- Jacob Just-Bomholt, CEOBuyabout 9.9 m SEK
- Jan Kimpen, board memberBuyabout 518 thousand SEK
- Christopher Busch, senior executiveBuyabout 1.1 m SEK
Earnings report
Next report: · Add to calendar · Google Calendar
On its last 15 report days Elekta usually moved about 4.7%. On a normal day it moves 1.1%.
−3.01% −13.18% +0.53% +23.48%
10,000 SEK in Elekta bought on November 7, 2016 is worth 10,100 SEK today, with dividends reinvested.
What would 10,000 SEK in Elekta be worth today? →
What would 10,000 SEK in Elekta be worth today?
10,100 SEK
with dividends reinvested, bought on November 7, 2016.
At worst it was worth 6,730 SEK (November 21, 2025).
The five biggest days of the journey
· +23.5% · the whole market rose 0.8% the same day · report day
· +18.8% · the whole market fell 1.7% the same day · report day
· −18.0% · the whole market rose 0.9% the same day · report day
· +15.8% · the whole market rose 4.9% the same day
· +14.6% · the whole market rose 2.3% the same day
Earlier days
+1.76% market −0.11% Elekta rose slightly over the week while the Stockholm market was roughly flat. Read →
Elekta rose slightly over the week while the Stockholm market was roughly flat.
The move was ordinary for the stock, and the share price stayed near its one-year high.
No company news clearly explains the gain; the Foundation items are routine.
Short sellers, who bet on a fall, trimmed their positions early in the week, which can ease pressure on the price.
+1.75% market −0.32% Elekta rose, moving against a slightly weaker market. Read →
Elekta rose, moving against a slightly weaker market.
No company news explains the move, and it was not an unusually large day for the stock.
Over the last five trading days, Elekta rose clearly while OMX Stockholm 30 rose slightly, so the stock outpaced the market.
Its share price stands near its highest close of the past year, and the stock is far above its low from last November.
Trading volume was around its usual level.
+3.00% market +0.83% Elekta rose sharply without a company-news explanation. Read →
Elekta rose sharply without a company-news explanation.
Over the same day the market rose clearly, so Elekta moved more than the market.
Over the last five trading days Elekta rose slightly, roughly in line with OMX Stockholm 30.
Elekta's shares sit near their highest close of the past year, and trading volume was around normal.
Healthcare peers fell slightly over the same days, so the sector did not drive the move.
+2.05% market −0.29% Elekta rose, moving against a slightly weaker OMX Stockholm 30. Read →
Elekta rose, moving against a slightly weaker OMX Stockholm 30.
No company news explains the move.
Over the last five trading days, Elekta rose clearly, in line with the market.
The next earnings report, a quarterly results release, is due on Wednesday 25 November 2026.
+3.65% market +3.01% Elekta rose clearly over the week, moving in line with the Stockholm market. Read →
Elekta rose clearly over the week, moving in line with the Stockholm market.
Trading was quieter than usual.
The market's broader upward move likely drove most of it, since no major company event fell in the week.
The Nomination Committee for the 2027 annual general meeting was named on Friday, a routine governance step.
+3.57% market +0.33% Elekta rose, moving well apart from a market that rose only slightly. Read →
Elekta rose, moving well apart from a market that rose only slightly.
No company news from that session explains the move.
Over the last five trading days, Elekta rose sharply, a big move for the stock, while the Stockholm market rose slightly.
Earlier news, including a letter of intent for ten linear accelerator systems (cancer radiation machines) from Evervie Health, came before the session and does not explain the move.
Short sellers' reported positions, bets against the stock, fell over the period, which can ease pressure on a share price but does not prove why it moved.
−1.79% market +0.96% Elekta fell clearly while the market rose clearly. Read →
Elekta fell clearly while the market rose clearly.
Over the last five trading days, Elekta rose clearly while the broader market was roughly flat.
Trading volume was well below its usual level, so the move happened on thin activity.
Elekta's next earnings report is due on 25 November 2026.
+1.30% market +1.57% Elekta rose, moving in line with the market. Read →
Elekta rose, moving in line with the market.
No company news explains it.
Over the last five trading days, Elekta rose clearly while the OMX Stockholm 30 fell slightly.
Trading was well below its usual level, so the move may reflect thin trading.
Elekta reports earnings on Wednesday 25 November 2026.
+2.31% market +0.41% Elekta rose clearly, moving more than the market, which was up slightly. Read →
Elekta rose clearly, moving more than the market, which was up slightly.
No company news explains the move.
Over the last five trading days, Elekta rose slightly while the OMX Stockholm 30 fell sharply, so it held up against the market.
Its shares sit well above the lowest close of the past year and below the highest, set in late May.
Elekta's next earnings report is due on 25 November, the next company event to watch.
+0.96% market −3.67% Elekta rose slightly over the last five trading days while the Stockholm market fell sharply. Read →
Elekta rose slightly over the last five trading days while the Stockholm market fell sharply.
The stock moved against the market, which is unusual for a healthcare name.
The main company news was a letter of intent from Evervie Health for ten Harmony Linac systems, a cancer radiotherapy equipment order worth about $15 million, signed early in the week.
A short seller, a fund betting on a fall in the share price, also exited its position.
−1.93% market −0.89% Elekta fell clearly, more than the broader OMX Stockholm 30 index, which also fell clearly. Read →
Elekta fell clearly, more than the broader OMX Stockholm 30 index, which also fell clearly.
No company news from that session explains the drop, so the move looks mostly market-driven.
Over the last five trading days, Elekta rose slightly while the market was roughly flat.
Trading volume was around its usual level, so the move was not driven by unusually heavy trading.
+2.70% market +1.25% Elekta rose sharply, moving well ahead of a market that also climbed. Read →
Elekta rose sharply, moving well ahead of a market that also climbed.
Over the last five trading days, Elekta also rallied strongly, outpacing a modestly higher market.
Earlier in the week, Gamma Knife and ASTRO data were in focus, and some commentary argued the shares sat below fair value, which may have supported sentiment.
The next earnings report on 25 November 2026 is the event to watch.
+4.78% market +1.19% Elekta rose sharply over the last five trading days, clearly more than the broader Stockholm market, which edged up. Read →
Elekta rose sharply over the last five trading days, clearly more than the broader Stockholm market, which edged up.
Much of the news in the window was about clinical data from its Gamma Knife and ASTRO radiation-therapy systems, which likely supported sentiment as investors weighed whether the shares looked cheap against estimates of fair value.
Some analyst commentary pulled the other way: a late-week report noted analysts keeping pressure on valuations, which likely tempered the gains at times.
Looking ahead, the next earnings report is due on 25 November 2026, which is the event to watch for fresh information on sales and profitability.
Learn more · Why do stocks go up and down?